Changes in lipid profiles in two groups of HIV-1 infected patients in cameroon on two treatment regimens with either efavirenz or nevirapine, in association with reverse transcriptase inhibitors

Journal of Medical Sciences

Volumn 10, Issue 2, 2010, Pages 25-33

  Nguemaim N F ^a   Mbuagbaw, J ^a,b   Nkoa, T ^a,c   Teto G ^a   Njitchouang, G R ^a   Pouomogne, D J ^a   Same Ekobo A ^a,d   Asonganyi, T ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITY OF BUEA   (Cameroon)

^c Yaounde Gynaeco Obstetric and Paediatric Hospital   (Cameroon)

^d UNIVERSITY OF DOUALA   (Cameroon)

Author keywords

Atherogenicity indices; Efavirenz; HIV type 1; Lipid profiles; Nevirapine

Indexed keywords

CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; CAMEROON; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLORIMETRY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 77954749322     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2010.25.33     Document Type: Article

References (53)

1. Allain, C.C., L.S. Poon, C.G. Chan, W. Richmond and P.C. Fu, 1974. Quantitative determination of serum cholesterol by the use of enzymes. Clin. Chem., 20: 470-475.
2. Assmann, G., H. Schulte, A. von Eckardstein and Y. Huang, 1996. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 124: S11-S20.
3. Behrens, G., A. Dejam, H. Schmidt, H.S. Balks and G. Brabant et al., 1999. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS, 13: F63-F70.
4. Bernasconi, E., A. Carota, L. Magenta, M. Pons, M. Russott and T. Moccetti, 1998. Metabolic changes in HIV-infected patients treated with protease inhibitors. Int. Conf. AIDS., 12: 88-88.
5. Bertold, H.K., K.G. Parhofer, M.M. Ritter, M. Addo and J.C. Wasmuth et al., 1999. Influence of protease inhibitor therapy on lipoprotein metabolism. J. Int. Med., 246: 567-575.
6. Bonnet, F., M. Savès, C. Droz, E. Peuchant, G. Chêne J. Beylot and P. Morlat, 2000. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J. Acquir. Immune. Defic. Syndr., 25: 199-200.
7. Bozzette, S.A., C.F. Ake, H.K. Tam, S.W. Chang and T.A. Louis, 2003. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med., 348: 702-710.
8. Buccolo, G. and H. David, 1973. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem., 19: 476-482.
9. Carr, A., J. Miller, M. Law and D.A. Cooper, 2000. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS, 14: F25-F32.
10. Carr, A., K. Samaras, A. Thorisdottir, G.R. Kaufmann, D.J. Chisholm and D.A. Cooper, 1999. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet, 353: 2093-2099.
11. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D.J. Chisholm and D.A. Cooper, 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12: 51-58.
12. Castelli, W.P., 1988. Cholesterol and lipids in the risk of coronary artery disease: The framingham heart study. Can. J. Cardiol., 4: A5-A10.
13. Clotet, B., M. van der Valk, E. Negredo and P. Reiss, 2003. Impact of nevirapine on lipid metabolism. JAIDS, 34: S79-S84.
14. Danwe, C., G. Atchou, M. Nkam, J. Mbuagbaw and R. Mougnoutou et al., 2005. Effects of antiretroviral therapy on lipid metabolism in HIV/AIDS subjects in cameroon. J. Med. Sci., 5: 78-82.
15. Dong, K.L., L.L. Bausserman, M.M. Flynn, B.P. Dickinson and T.P. Flanigant et al., 1999. Changes in body habitus and serum lipid adnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J. Acquir. Immune. Defic. Syndr., 21: 107-113.
16. Dube, M.P., R. Zackin, P. Tebas, R. Roubenoff and K. Mulligan et al., 2002. Prospective study of regional body composition in antiretroviral-naïve subjects randomized to receive zidovudine plus lamivudine or didanosine plus stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Proceedings of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sept. 22-25, International Medical Press, San Diego, California, London, pp: 27-27.
17. Feingold, K.R., R.M. Krauss, M. Pang, W. Doerrle, P. Jensen and C. Grunfeld, 1993. The hypertriglyceridemia of acquired immunodeficiency syndrome associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab., 76: 1423-1427.
18. Fisac, C., E. Fumero, M. Crespo, B. Roson and N. Virgili et al., 2004. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir (ABC), efavirenz (EFV), or nevirapine (NVP): 24-Month results of randomised study. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infection, Feb. 8-11, Foundation for Retrovirology and Human Health, San Francisco, California. Alexandria, Virginia, pp: 105-105.
19. Fontas, E., F. van Leth, C.A. Sabin, N.F. Moller and M. Rickenback et al., 2004. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?. J. Infect. Dis., 189: 1056-1074.
20. Frick, H., O. Elo, K. Haapa, O.P. Heinonen and P. Heinsalmi et al., 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factor and incidence of coronary heart disease. N. Engl. J. Med., 317: 1237-1245.
21. Friedewald, W.T., R.I. Levy and D.S. Fredrickson, 1972. Estimation of the concentration of LDL cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18: 499-502.
22. Gordon, D.J., J.L. Probstfield, R.J. Garrison, J.D. Neaton and W.P. Castelli et al., 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79: 8-15.
23. Grundfeld, C., M. Pang, W. Doerrler, J.K. Shigenaga, P. Jensen and K.R. Feingold, 1992. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endecrinol. Metab., 74: 1045-1052.
24. Heath, K.V., R.S. Hogg, K.J. Chan, M. Harris and V. Montessori, M.V.O. Shanghnessy and J.S. Montanera, 2001. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS, 15: 231-239.
25. Henry, K., H. Melfroe, J. Huebesch, J. Hermundson and J. Simpson, 1998. Avorstatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet, 352: 1031-1032.
26. Lipid Research Clinics Program, 1984. The lipid research clinics coronary primary prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA, 251: 351-364.
27. Mallal, S.A., M. John, C.B. Moore, I.R. James and E.J. Mckinnon, 2000. Contribution of serum triglycerides by the use of enzymes. Clin. Chem., 19: 476-482.
28. Manninen, V., M.O. Elo, M.H. Frick, K. Haapa and P. Heinonen et al., 1988. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA, 260: 641-651.
29. Martinez, E., I. Conget, L. Lozano, R. Casamitjana and J.M. Gatell, 1999. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS., 13: 805-810.
30. McComsey, G.A., D.J. Ward, S.M. Hessenthaler, M.G. Sension and P. Shalit et al., 2004. Trial to assess the regression of Hyperlactatemia and to evaluate the regression of established lipodystrophy in HIV-1-positives subjects (TARHEEL; ESS40010) study team. Improvement in lipodystrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin. Infect. Dis., 38: 263-270.
31. Mildvan, D., S.G. Machado, I. Wilets and S.E. Grossbert, 1992. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet, 339: 453-456.
32. Molina, J.M., F. Ferchal, C. Rancinan, F. Raffi and W. Rozenbaum et al., 2000. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J. Infect. Dis., 182: 599-602.
33. Mooser, V. and A. Carr, 2001. Antiretroviral therapy associated hyperlipidemia in HIV-1 disease. Curr. Opin. Lipid, 3: 313-319.
34. Moyle, G., C. Baldwin, S. Mandalia, S. Comitis, P. Burn and B. Gazzard, 2001. Changes in metabolic parameters and body shape. after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: Single-arm observational cohort. J. Acquired Immune Defic. Syndr., 28: 399-401.
35. Mulligan, K., C. Grunfeld, V.W. Tai, H. Algren and M. Pang et al., 2000. Hyperlipidaemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. JAIDS, 23: 35-43.
36. Negredo, E., L. Cruz, R. Paredes, L. Ruiz and C.R. Fumaz et al., 2002. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patient with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis., 34: 504-510.
37. Ngondi, L.J., S.H.L. Etame, M. Fonkoua, H. Yangoua and J. Oben, 2007. Lipid profile of infected patients treated with highly active antiretroviral therapy in cameroon. J. Med. Sci., 7: 670-673.
38. Nguemaïm, N.F., J. Mbuagbaw, T. Nkoa, G. Alemnji and G. Této et al., 2010. Serum lipid profile in HIV highly active antiretriviral therapy-naïve patients in Cameroon: a case-control study. HIV Med., 10.1111/j.1468-1293.2009.00784.x
39. Nolan, D. and S. Mallal, 2004. The role of the nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J. HIV Ther., 9: 34-40.
40. Nolan, D., E. Hammond, I. James, E. Mckinnon and S. Mallal, 2003. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther., 8: 617-626.
41. Nunez, M., V. Soriano, L.M. Carbonero, A. Barrios and P. Barriero et al., 2002. SENC (Spanish, efavirenz, vs. nevirapine comparison) trial: A randomized open-label trial, the 2NN study. Lancet, 363: 1253-1263.
42. Periard, D., A. Telenti, P. Sudre, J.J. Chesaux and P. Halfon et al., 1999. Atherogenic dyslipideamia in HIV-infected individuals treated with protease inhibitors. The Swiss cohort study. Circulation, 100: 700-705.
43. Riddler, S.A., E. Smit, S.R. Cole, R. Li, J.S. Chmiel, A. Dobs and F. Pallela, 2003. Impact of HIV infection and HAART on serum lipid in men. JAMA, 289: 2978-2982.
44. Roberts, A.D., R.A. Muesing, D.M. Parenti, J. Hsia, A.G. Wasserman and G.L. Simon, 1999. Alteration in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus infected patients. Clin. Infect. Dis., 29: 441-443.
45. Robins, S.J., 2001. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the veterans affairs high-density lipoprotein international trial. Am. J. Cardiol., 88: 19-23.
46. Rubins, H.B., S.J. Robins, D. Collins, C.L. Fye and J.W. Anderson et al., 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group. N. Engl. J. Med., 341: 410-418.
47. Sattler, F., 2003. Body habitus changes related to lipodystrophy. Clin. Infect. Dis., 36: 84-90.
48. Smith, C.J., I. Levy, C.A. Sabin, E. Kaya, M.A. Johnson and M.C. Lipman, 2004. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med., 5: 88-92.
49. Stein, J.H., Y. Wu, H. Kawabata and U.H. Iloeje, 2003. Increase use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. J. Cardiol., 92: 270-274.
50. Tashima, K.T., L. Bausserman, E.N. Alt, E. Aznar and T.P. Flanigan, 2003. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clin. Trials., 4: 29-36.
51. Van Leth, F., P. Phanuphak, E. Stroes, B. Gazzard and P. Cahn et al., 2004. Nevirapine and Efavirenz elicit different changes in lipid profiles in Antiretroviral-Therapy-Naïve patients infected with HIV-1. Plos Med., 1: 64-74.
52. Van der valk, M., J.J. Kastelein, R.L. Murphy, F. van Leth and C. Katlama et al., 2001. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS, 15: 2407-2414.
53. Warnick, G.R. and J.J. Aberers, 1978. A comprehensive evaluation of heparin-manganese precipitation cholesterol. J. Lipid Res., 19: 65-76.